# Synthesis and Biological Evaluation of 4-(3-Hydroxy-benzofuran-2-yl)coumarins

Authors: Puttaraju Boregowda; Shivashankar Kalegowda; Vijaykumar Pandurang Rasal; Jagadeeshreddy Eluru; Ebenezer Koyye
Journal: Organic Chemistry International
 (2014)

---

## Abstract

Various 4-bromomethylcoumarins (1a-k) were reacted with methyl salicylate to yield 2-(2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid methyl esters (2a-k). Formations of (3a-k) were achieved by using DBU under microwave irradiation. Structures of all the compounds were established on the basis of their spectral data. All the compounds were tested in vitro for their antimicrobial activity and cell cytotoxicity. All the tested compounds (2b-k) and (3a-k) were shown to be better activity against Staphylococcus aureus than the standard Ciprofloxacin. The compound (3k) (R = 6-OMe) was found to be more potent cytotoxic than the standard 5-fluorouracil.


---

## Body

## 1. Introduction

Benzofuran and its derivatives [1] have attracted considerable interest in recent years for their versatile properties in chemistry and pharmacology. 3-Benzofuran-5-aryl-1-pyrazolylcarbonyl-4-oxo-naphthyridin [2] was found to be the most potent antitubercular agent againstMycobacterium tuberculosis, even better than standard drugisoniazid. Benzofuran derivatives [3] were found to exhibit favorable antibacterial activity againstStaphylococcus aureus andBacillus subtilis which were better than the control drugsCefotaxime andKetoconazole. 2-Phenylbenzofurans [4] exhibited enhanced antiprotozoal activity againstTrypanosoma brucei rhodesiense andPlasmodium falciparum. 2-Arylbenzofurans [5] were isolated from the roots ofGlycyrrhiza uralensis. They showed significantin vitro protein tyrosine phosphate-1B inhibitory activity. Technetium-99m labeled pyridyl benzofuran derivatives [6] was tested as potential probes for imaging β-amyloid plaques in Alzheimer’s brains using single photon emission computed tomography.Coumarin moieties are widely featured in a broad range of pharmacological and biologically active compounds [7, 8]. Phosphorohydrazine derivatives of coumarin displayed highin vivo antitumour activity against P388 leukemia [9]. Coumarin pyrazoline hybrids were found to possess the highest cytotoxicity against colorectal cell line HCT-116 with IC50 value of 0.01 μM [10]. Thiazolyl coumarin derivatives showed significant inhibition against Haemophilus influenzae with a MIC value of 15 μM which is less than that of tetracycline [11]. Benzo[d]thiazolyl coumarins [12] demonstrated anti-HIV activity against HIV-1 cell with EC50 < 7 μg/mL.Based on the survey of recent literature studies on coumarins and benzofurans and in our effort to discover novel antimicrobial [13–16] and anticancer agents [17, 18], the aim of our work is synthesis of 4-(3-hydroxy-benzofuran-2-yl)coumarins and the evaluation of them for their therapeutic importance.


## 2. Chemistry

The synthetic scheme for the target molecules was initiated by the Pechmann cyclisation of phenols with 4-bromoethylacetoacetate [19] leading to the required 4-bromomethylcoumarins [20–22] (1a-k). The compound 4-(6-methyl-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid methyl ester [23] (2a) (R = 6-CH3) was synthesized by reacting 4-bromomethyl-6-methylcoumarin and methyl salicylate in the presence of anhydrous K2CO3. Using this method, the compounds (2b-k) were synthesized. These intermediates (2a-k) did not yield the products (3a-k) in the presence of DBU in DMF under thermal conditions. However, when subjected to microwave irradiation afforded the compounds (3a-k) (Scheme 1). The completion of the reaction is monitored by TLC. A plausible mechanistic pathway proposed for the title compounds involves the generation of a carbanion at the active methylene group (C4–CH2) which is stabilized by coumarin ring [24]. The intramolecular ring closure occurred when carbanion attacked the carbonyl carbon of methyl ester and eliminated methanol to form 4-(3-oxo-2,3-dihydro-benzofuran-2-yl)-coumarins that underwentin situ aromatization under the reaction conditions to yield 4-(3-hydroxy-benzofuran-2-yl)-coumarins (Figure 1). The high melting solids separated in the reaction mixture were filtered off to obtain compounds (3a-k) as crystalline solids.Scheme 1
Synthesis of compounds (2a-k) and (3a-k).Figure 1
Plausible mechanism for the synthesis of (3a-k).


## 3. Results and Discussion

The structures of novel (2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid methyl esters and 4-(3-hydroxy-benzofuran-2-yl)-coumarins were established from IR, 1H NMR, 13C NMR, and LC-MS data as illustrated for a representative example. In the IR spectrum of 2-(7-methyl-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid methyl ester (2b) (R = 7-CH3), the lactone carbonyl stretching frequency was appeared at 1720 cm−1, whereas the methyl ester carbonyl stretching frequency was observed at 1742 cm−1. The 1H NMR spectrum of the compound (2b) displayed a singlet at δ 2.40, 3.85, 5.52, and 6.85 due to CH3, OCH3, OCH2, and C3–H protons, respectively. The aromatic protons resonated as a multiplet at δ 7.10–7.83.The IR spectrum of the compound 4-(3-hydroxy-benzofuran-2-yl)-6-methylcoumarin (3a) (R = 6-CH3) displayed a lactone carbonyl stretching frequency at 1729 cm−1, whereas the –OH stretching frequency appeared at 3450 cm−1. The 1H NMR spectrum of the compound (3a) showed a singlet at δ 2.42 and 6.93 due to CH3 and C3–H protons, respectively. The aromatic protons were resonated as a multiplet at δ 7.23–8.48. The –OH proton observed as a singlet at δ 11.42 that was confirmed by D2O exchange. The mass spectrum (LC-MS) of the compound (3g) displayed a [M+H] peak at 307. The 13C NMR spectral data of compound (3h) are given in the experimental section.


## 4. Antimicrobial Activity

All the newly synthesized compounds (2b-k) and (3a-k) were screened for their antibacterial and antifungal activity at different concentrations of 100, 50, 25, 12.5, 6.25, 3.125, 1.6, 0.8, and 0.2 μg/mL via broth microdilution method. The minimum inhibitory concentrations (MIC) were determined by serial dilution method [25].Antibacterial activity was carried out against three Gram-positive bacteria, namely,Staphylococcus aureus, Enterococcus faecalis, andStreptococcus mutans, and three Gram-negative bacteria, namely,Escherichia coli, Klebsiella pneumonia,andPseudomonas aeruginosa.Ciprofloxacin was used as a standard. Antifungal activity was carried out against two fungi, namely,Candida albicans andAspergillus fumigatus.Fluconazole was used as a standard.The investigation of antimicrobial screening data (Table1) showed that most of the tested compounds exhibited good bacterial and fungal inhibition. The compounds (2b) (R = 7-CH3), (2c) (R = 6-Cl), (2e) (R = 6-F), and (2f) (R = 5,6-benzo) were found to be very active againstS. mutanswith MIC of 0.2 μg/mL. The compounds (2c) (R = 6-Cl) and (2i) (R = 6-tert-butyl) were found to be highly active againstE. coli with MIC of 0.2 μg/mL. The compound (2i) (R = 6-tert-butyl) displayed high activity againstA. fumigatuswith MIC of 0.2 μg/mL. The compounds (3a) (R = 6-CH3) and (3b) (R = 7-CH3) were found to be highly active againstS. aureus,E. faecalis,andS. mutanswith MIC of 0.2 μg/mL. The compounds (3e) (R = 6-F) and (3f) (R = 5,6-benzo) were found to be highly active againstS. aureus andC. albicans with MIC of 0.2 μg/mL. The compounds (3g) (R = 6,8-dimethyl), (3h) (R = 6-isopropyl), (3i) (R = 6-tert-butyl), and (3j) (R = 6-benzyl) exhibited high activity againstS. aureus,S. mutans,andC. albicans with MIC of 0.2 μg/mL. The compound (3k) (R = OMe) showed high activity againstS. aureus andC. albicans with MIC of 0.2 μg/mL. It is to be noted that most of these compounds exhibited moderate activity againstP. aeruginosaand inactive againstK. pneumonia.Table 1
Results of antimicrobial activities of the synthesized compounds (2b–k) and (3a–k) MICs (μg/mL).
Compounds
Gram-positive
Gram-negative
Fungi
Number
R
S. aureus
E. faecalis
S. mutans
E. coli
K. pneumonia
P. aeruginosa
C. albicans
A. fumigatus
2b
7-CH3
0.4
50
0.2
6.25
100
6.25
12.5
0.4
2c
6-Cl
0.4
1.6
0.2
0.2
50
3.12
12.5
0.4
2d
6-Br
0.8
25
0.4
1.6
100
3.12
12.5
0.4
2e
6-F
0.4
3.12
0.2
1.6
100
6.25
>100
0.8
2f
5,6-benzo
0.4
50
0.2
6.25
100
6.25
12.5
0.4
2g
6,8-dimethyl
1.6
0.8
0.8
3.12
100
50
100
1.6
2h
6-isopropyl
0.8
6.25
0.4
0.4
100
25
12.5
0.4
2i
6-tert-butyl
0.8
6.25
0.8
0.2
100
25
12.5
0.2
2j
6-benzyl
0.8
12.5
0.4
1.6
100
6.25
100
0.8
2k
6-OMe
0.8
3.12
0.8
3.12
100
100
100
0.8
3a
6-CH3
0.2
0.2
0.2
50
100
50
12.5
—
3b
7-CH3
0.2
0.2
0.2
100
50
>100
0.2
—
3c
6-Cl
0.2
0.4
0.2
100
100
25
3.12
—
3d
6-Br
—
—
—
—
—
—
—
—
3e
6-F
0.2
0.4
0.4
100
100
>100
0.2
—
3f
5,6-benzo
0.2
0.4
3.12
50
100
0.2
0.2
—
3g
6,8-dimethyl
0.2
0.4
0.2
100
100
50
0.2
—
3h
6-isopropyl
0.2
0.4
0.2
50
100
3.12
0.2
—
3i
6-tert-butyl
0.2
0.8
0.2
50
>100
6.25
0.2
—
3j
6-benzyl
0.2
0.8
0.2
100
100
50
0.2
—
3k
6-OMe
0.2
0.4
3.12
50
100
6.25
0.2
—
Ciprofloxacin
2
2
2
1
1
4
—
—
Fluconazole
—
—
—
—
—
—
16
8In general, uncyclized compounds (2b-k) are more potent than the cyclized compounds (3a-k) againstS. mutans andE. coli. The cyclized compounds (3a-k) are more potent than the uncyclized compounds (2b-k) againstE. faecalisandC. albicans. It is interesting to found that both cyclized and uncyclized compounds showed better activity againstS. aureusthan the standardCiprofloxacin.


## 5.In Vitro Cell Cytotoxicity

All the newly synthesized compounds (2b-k) and (3a-k) were evaluated for their cytotoxicity against DAL cell using trypan blue dye exclusion assay. The detail procedure has been described in our earlier publications [26, 27].The investigation ofin vitro cell cytotoxicity (Table 2) revealed that most of the tested compounds exhibited good activity. The compounds (2d) (R = 6-Br), (2h) (R = 6-isopropyl), (2i) (R = 6-tert-butyl), (2j) (R = 6-benzyl), (2k) (R = 6-OMe), (3a) (R = 6-CH3), (3c) (R = 6-Cl), (3f) (R = 5,6-benzo), (3g) (R = 6,8-dimethyl), (3h) (R = 6-isopropyl), (3i) (R = 6-tert-butyl), and (3k) (R = 6-OMe) were found to be highly active (>70%) against DAL cell at the concentration of 100 μg/mL. The compound (2f) (R = 5,6-benzo) was found to be poor active (25%) against DAL cell at the concentration of 100 μg/mL. The rest of the compounds were found to be moderately active (>40%). In general, the cyclized compounds (3a-k) were found to be more potent than the uncyclized compounds (2b-k).Table 2
Results ofin  vitro cytotoxicity of the synthesized compounds (2b–k) and (3a–k) against Dalton’s Ascitic Lymphoma cell (1
×
10
5) at the concentration of 100 μg/mL.
Number of compounds
R
Number of cells
% of dead cells
Live
Dead
2b
7-CH3
49
51
51
2c
6-Cl
41
59
59
2d
6-Br
19
81
81
2e
6-F
42
58
58
2f
5,6-benzo
75
25
25
2g
6,8-dimethyl
55
45
45
2h
6-isopropyl
12
88
88
2i
6-tert-butyl
16
84
84
2j
6-benzyl
13
87
87
2k
6-OMe
18
82
82
3a
6-CH3
21
79
79
3b
7-CH3
56
44
44
3c
6-Cl
15
85
85
3d
6-Br
—
—
—
3e
6-F
34
66
66
3f
5,6-benzo
13
87
87
3g
6,8-dimethyl
21
79
79
3h
6-isopropyl
26
74
74
3i
6-tert-butyl
15
85
85
3j
6-benzyl
53
47
47
3k
6-OMe
11
89
89
5-Fluorouracil
—
12
88
88


## 6. Experimental Section

The melting points were measured with an electric melting point apparatus and are uncorrected. The IR spectra were obtained using a Shimadzu-8400S FT-IR spectrophotometer.1H NMR and 13C NMR spectra in DMSO-d
6 solution were recorded at 25°C on a Bruker 300 and 400 MHz spectrometer, respectively. The 1H chemical shifts were reported in δ ppm and referenced to TMS. The mass spectra were recorded on an Agilent-Single Quartz LC-MS. The purity of the compounds was checked by TLC. Microwave reactions were carried out on Milestone Laboratory’s microwave reactor. The elemental analyses were carried out using Elemental Vario Micro Cube CHNS Rapid Analyzer. All the compounds gave satisfactory elemental analysis.General Procedure for the Synthesis of Compounds (
2a
-
k
). Methyl salicylate (0.304 g, 2.0 mmol) and anhydrous K2CO3 (1.38 g, 10 mmol) were stirred in 25 mL of dry acetone for 30 min. 4-Bromomethylcoumarin (1a-k) (2.0 mmol) was added and stirring was continued for 24 h. The reaction mixture was concentrated to one-fourth volume and poured onto crushed ice. The solid separated was filtered and washed with 10 mL of 5% HCl. Then, it was washed with 50 mL of cold water. The crude product was dried and recrystallised from ethanol.2-(7-Methyl-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid methyl ester (
2b
). Yield 90%; colorless solid; mp. 168–170°C; IR (KBr, cm−1): 1720 (lactone C=O), 1742 (methyl ester, C=O); 1H NMR (300 MHz, DMSO-d
6): δ 2.40 (s, 3H, CH3), 3.85 (s, 3H, OCH3), 5.52 (s, 2H, OCH2), 6.85 (s, 1H, C3–H), 7.10–7.83 (m, 7H, Ar–H) ppm; Anal. Cald. for C19H16O5: C, 70.36; H, 4.97. Found: C, 70.27; H, 4.89.2-(6-Chloro-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid methyl ester (
2c
). Yield 92%; colorless solid; mp. 188–191°C; IR (KBr, cm−1): 1730 (lactone C=O), 1750 (methyl ester C=O); 1H NMR (300 MHz, DMSO-d
6): δ 3.81 (s, 3H, OCH3), 5.46 (s, 2H, OCH2), 6.90 (s, 1H, C3–H), 7.07–8.04 (m, 7H, Ar–H) ppm; Anal. Cald. for C18H13ClO5: C, 62.71; H, 3.80. Found: C, 62.65; H, 3.73.2-(6-Bromo-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid methyl ester (
2d
). Yield 89%; yellow solid; mp. 147–149°C; IR (KBr, cm−1): 1714 (lactone C=O), 1750 (methyl ester C=O); 1H NMR (300 MHz, DMSO-d
6): δ 3.85 (s, 3H, OCH3), 5.49 (s, 2H, OCH2), 6.79 (s, 1H, C3–H), 7.12–7.82 (m, 7H, Ar–H) ppm; Anal. Cald. for C18H13BrO5: C, 55.55; H, 3.37. Found: C, 55.48; H, 3.32.2-(6-Fluoro-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid methyl ester (
2e
). Yield 90%; colorless solid; mp. 186–149°C; IR (KBr, cm−1): 1724 (lactone C=O), 1739 (methyl ester C=O); 1H NMR (300 MHz, DMSO-d
6): δ 3.86 (s, 3H, OCH3), 5.50 (s, 2H, OCH2), 6.92 (s, 1H, C3–H), 7.10–8.12 (m, 7H, Ar–H) ppm; Anal. Cald. for C19H15FO4: C, 69.93; H, 4.63. Found: C, 69.86; H, 4.58.2-(5,6-Benzo-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid methyl ester (
2f
). Yield 90%; light yellow solid; mp. 183–186°C; IR (KBr, cm−1): 1728 (lactone C=O), 1746 (methyl ester C=O); 1H NMR (300 MHz, DMSO-d
6): δ 3.83 (s, 3H, OCH3), 5.95 (s, 2H, OCH2), 7.12–8.42 (m, 11H, Ar–H) ppm; Anal. Cald. for C22H16O5: C, 73.33; H, 4.48. Found: C, 73.26; H, 4.40.2-(6,8-Dimethyl-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid methyl ester (
2g
). Yield 91%; colorless solid; mp. 193–195°C; IR (KBr, cm−1): 1727 (lactone C=O), 1739 (methyl ester C=O); 1H NMR (300 MHz, DMSO-d
6): δ 2.36 (d, 6H, 6,8-dimethyl), 3.85 (s, 3H, OCH3), 5.47 (s, 2H, OCH2), 6.84 (s, 1H, C3–H), 7.08–7.82 (m, 6H, Ar–H) ppm; Anal. Cald. for C22H22O5: C, 71.10; H, 5.36. Found: C, 71.03; H, 5.29.2-(6-Isopropyl-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid methyl ester (
2h
). Yield 97%; colorless solid; mp. 179–182°C; IR (KBr, cm−1): 1718 (lactone C=O), 1746 (methyl ester C=O); 1H NMR (300 MHz, DMSO-d
6): δ 1.27 (d, 6H, 2-CH3 of isopropyl), 3.02 (m, 1H, CH of isopropyl), 3.88 (s, 3H, OCH3), 5.55 (s, 2H, OCH2), 6.88 (s, 1H, C3–H), 7.10–7.87 (m, 7H, Ar–H) ppm; Anal. Cald. for C21H20O5: C, 71.58; H, 5.72. Found: C, 71.50; H, 5.66.2-(6-Tert-butyl-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid methyl ester (
2i
). Yield 89%; colorless solid; mp. 172–173°C; IR (KBr, cm−1): 1716 (lactone C=O), 1728 (methyl ester C=O); 1H NMR (300 MHz, DMSO-d
6): δ 1.37 (s, 9H, 6-tert-butyl), 3.81 (s, 3H, OCH3), 5.53 (s, 2H, OCH2), 6.93 (s, 1H, C3–H) 7.23–7.91 (m, 7H, Ar–H) ppm; Anal. Cald. for C21H20O5: C, 72.00; H, 6.05. Found: C, 71.83; H, 5.97.2-(6-Benzyl-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid methyl ester (
2j
). Yield 89%; colorless solid; mp. 172–175°C; IR (KBr, cm−1): 1712 (lactone C=O), 1738 (methyl ester C=O); 1H NMR (300 MHz, DMSO-d
6): δ 3.84 (s, 3H, OCH3), 4.03 (s, 2H, C6–CH2), 5.51 (s, 2H, OCH2), 6.86 (s, 1H, C3–H), 7.10–7.89 (m, 12H, Ar–H) ppm; Anal. Cald. for C25H20O5: C, 74.99; H, 5.03. Found: C, 74.91; H, 4.95.2-(6-Methoxy-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid methyl ester (
2k
). Yield 95%; colorless solid; mp. 174–176°C; IR (KBr, cm−1): 1720 (lactone C=O), 1739 (methyl ester C=O); 1H NMR (300 MHz, DMSO-d
6): δ 3.85 (d, 6H, 6-OCH3, OCH3), 5.52 (s, 2H, OCH2), 6.84 (s, 1H, C3–H), 7.13–7.82 (m, 7H, Ar–H) ppm; Anal. Cald. for C19H16O6: C, 67.05; H, 4.74. Found: C, 66.97; H, 4.67.General Procedure for the Synthesis of Compounds (
3a
-
k
). A mixture of 2-(2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid methyl ester (2a-k) (2.0 mmol), DBU (0.3 g, 2.0 mmol) and DMF (25 mL) were added to a microwave tube equipped with a magnetic stir bar. The microwave tube was fitted with a reflux condenser and irradiated in a microwave reactor at a temperature of 140°C for 4 min at a maximum power of 370 W. Then, completion of the reaction mixture was poured onto ice cold water and neutralized with dil HCl solution. The solid separated was filtered and washed with 100 mL of cold water. The crude product was dried and recrystallised from ethanol.4-(3-Hydroxy-benzofuran-2-yl)-6-methyl-chromen-2-one (
3a
). Yield 90%; yellow solid; mp. 221–224°C; IR (KBr, cm−1): 1729 (lactone C=O), 3450 (OH); 1H NMR (300 MHz, DMSO-d
6): δ 2.42 (s, 3H, 6-CH3), 6.93 (s, 1H, C3–H), 7.23–8.48 (m, 7H, Ar–H), 11.42 (s, 1H, OH, D2O exchangeable) ppm; Anal. Cald. for C18H12O4: C, 73.97; H, 4.14. Found: C, 73.89; H, 4.07.4-(3-Hydroxy-benzofuran-2-yl)-7-methyl-chromen-2-one (
3b
). Yield 93%; yellow solid; mp. 229–232°C; IR (KBr, cm−1): 1730 (lactone C=O), 3440 (OH); 1H NMR (300 MHz, DMSO-d
6): δ 2.43 (s, 3H, 7-CH3), 6.91 (s, 1H, C3–H), 7.21–8.42 (m, 7H, Ar–H), 11.22 (s, 1H, OH) ppm; Anal. Cald. for C18H12O4: C, 73.97; H, 4.14. Found: C, 73.89; H, 4.08.4-(3-Hydroxy-benzofuran-2-yl)-6-chloro-chromen-2-one (
3c
). Yield 86%; yellow solid; mp. 260–263°C; IR (KBr, cm−1): 1743 (lactone C=O), 3460 (OH); 1H NMR (300 MHz, DMSO-d
6): δ 7.04 (s, 1H, C3–H), 7.34–8.61 (m, 7H, Ar–H), 11.66 (s, 1H, OH) ppm; Anal. Cald. for C17H9ClO4: C, 65.30; H, 2.90. Found: C, 65.19; H, 2.81.4-(3-Hydroxy-benzofuran-2-yl)-6-bromo-chromen-2-one (
3d
). Yield 90%; yellow solid; mp. 247–250°C; IR (KBr, cm−1): 1736 (lactone C=O), 3435 (OH); 1H NMR (300 MHz, DMSO-d
6): δ 7.00 (s, 1H, C3–H), 7.35–8.70 (m, 7H, Ar–H), 11.65 (s, 1H, OH) ppm; Anal. Cald. for C17H9BrO4: C, 57.14; H, 2.54. Found: C, 57.02; H, 2.41.4-(3-Hydroxy-benzofuran-2-yl)-6-flouro-chromen-2-one (
3e
). Yield 84%; yellow solid; mp. 242–244°C; IR (KBr, cm−1): 1723 (lactone C=O), 3456 (OH); 1H NMR (300 MHz, DMSO-d
6): δ 7.06 (s, 1H, C3–H), 7.35–8.63 (m, 7H, Ar–H), 11.70 (s, 1H, OH) ppm; Anal. Cald. for C17H9FO4: C, 68.92; H, 3.06. Found: C, 68.80; H, 2.93.4-(3-Hydroxy-benzofuran-2-yl)-5,6-benzo-chromen-2-one (
3f
). Yield 89%; yellow solid; mp. 222–225°C; IR (KBr, cm−1): 1725 (lactone C=O), 3409 (OH); 1H NMR (300 MHz, DMSO-d
6): δ 6.99 (s, 1H, C3–H), 7.25–9.30 (m, 10H, Ar–H); 11.5 (s, 1H, OH) ppm; Anal. Cald. for C21H12O4: C, 76.82; H, 3.68. Found: C, 76.70; H, 3.54.4-(3-Hydroxy-benzofuran-2-yl)-6,8-dimethyl-chromen-2-one (
3g
). Yield 91%; colorless solid; mp. 228–231°C; IR (KBr, cm−1): 1719 (lactone C=O), 3416 (OH); 1H NMR (300 MHz, DMSO-d
6): δ 2.35 (d, 6H, 6,8-dimethyl), 6.92 (s, 1H, C3–H), 7.30–8.15 (m, 6H, Ar–H), 10.45 (s, 1H, OH) ppm; LC-MS: 307 [M + H]; Anal. Cald. for C20H18O5: C, 71.41; H, 5.36. Found: C, 71.28; H, 5.24.4-(3-Hydroxy-benzofuran-2-yl)-6-isopropyl-chromen-2-one (
3h
). Yield 93%; yellow solid; mp. 209–211°C; IR (KBr, cm−1): 1714 (lactone C=O), 3428 (OH); 1H NMR (300 MHz, DMSO-d
6): δ 1.26 (d, 6H, 2-CH3 of isopropyl), 3.00 (m, 1H, CH of isopropyl), 6.93 (s, 1H, C3–H), 7.33–8.42 (m, 7H, Ar–H), 11.41 (s, 1H, OH) ppm; 13C NMR (400 MHz, DMSO-d
6): δ 24.5, 32.3, 110.2, 111.9, 112.8, 117.5, 121.8, 125.6, 126.1, 127.4, 128.1, 129.3, 131.7, 145.2, 148.3, 157.6, 158.8, 158.6, 160.1 ppm; Anal. Cald. for C20H16O4: C, 74.99; H, 5.03. Found: C, 74.88; H, 4.92.4-(3-Hydroxy-benzofuran-2-yl)-6-tert-butyl-chromen-2-one (
3i
). Yield 93%; yellow solid; mp. 214–216°C; IR (KBr, cm−1): 1710 (lactone C=O), 3432 (OH); 1H NMR (300 MHz, DMSO-d
6): δ 1.37 (s, 9H, tert-butyl), 6.86 (s, 1H, C3–H), 6.92–8.58 (m, 7H, Ar–H), 11.42 (s, 1H, OH) ppm; Anal. Cald. for C21H18O4: C, 75.43; H, 5.03. Found: C, 75.32; H, 4.90.4-(3-Hydroxy-benzofuran-2-yl)-6-benzyl-chromen-2-one (
3j
). Yield 96%; yellow solid; mp. 224–227°C; IR (KBr, cm−1): 1717 (lactone C=O), 3422 (OH); 1H NMR (300 MHz, DMSO-d
6): δ 4.07 (s, 2H, C6–CH2), 6.96 (s, 1H, C3–H), 7.07–8.39 (m, 12H, Ar–H), 11.49 (s, 1H, OH) ppm; Anal. Cald. for C24H16O4: C, 78.25; H, 4.38. Found: C, 78.12; H, 4.26.4-(3-Hydroxy-benzofuran-2-yl)-6-methoxy-chromen-2-one (
3k
). Yield 95%; yellow solid; mp. 220–222°C; IR (KBr, cm−1): 1718 (lactone C=O), 3424 (OH); 1H NMR (300 MHz, DMSO-d
6): δ 3.81 (s, 3H, 6-OCH3), 6.99 (s, 1H, C3–H), 7.28–8.10 (m, 7H, Ar–H), 11.49 (s, 1H, OH) ppm; Anal. Cald. for C18H12O5: C, 70.13; H, 3.92. Found: C, 70.01; H, 3.81.


## 7. Conclusion

All the tested compounds (2b-k) and (3a-k) were shown to exhibit better activity againstStaphylococcus aureus than the standardCiprofloxacin. The compound (3k) (R = 6-OMe) was found to be more potent cytotoxic than the standard5-fluorouracil.



---

*Source: 297586-2014-03-27.xml*